Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Breast CancerLung CancerNeurotoxicityOvarian CancerProstate CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Amifostine

500 mg three times a week.

Trial Locations (15)

29303

CCOP - Upstate Carolina, Spartanburg

43215

CCOP - Columbus, Columbus

49503

CCOP - Grand Rapids, Grand Rapids

53405

All Saints Cancer Center at Wheaton Franciscan Healthcare, Racine

54449

CCOP - Marshfield Clinic Research Foundation, Marshfield

61801

CCOP - Carle Cancer Center, Urbana

62526

CCOP - Central Illinois, Decatur

64131

CCOP - Kansas City, Kansas City

65807

Cancer Research for the Ozarks, Springfield

71301

Christus St. Frances Cabrini Center for Cancer Care, Alexandria

76508

CCOP - Scott and White Hospital, Temple

67214-3882

CCOP - Wichita, Wichita

49007-3731

CCOP - Kalamazoo, Kalamazoo

77030-4009

University of Texas M.D. Anderson CCOP Research Base, Houston

98405-0986

CCOP - Northwest, Tacoma

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00078845 - Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter